OTC: SOLTF - Sosei Group Corporation

Rentabilité sur six mois: -34.7%
Secteur: Healthcare

Calendrier des promotions Sosei Group Corporation


À propos de l'entreprise

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis.

plus de détails
The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

EBITDA 273.3
EV/EBITDA -4.74
Industry Biotechnology
P/BV 0.0346
P/E 1.09
P/S 0.1604
Sector Health Care
Валюта usd
Валюта отчета usd
Выручка 1056.49
Див.доход ао 0
Дивиденд ао 1583.28
Сайт https://soseiheptares.com
Цена ао 10.53
Число акций ао 0.08252 млрд
Changement de prix par jour: 0% (6.1575)
Changement de prix par semaine: 0% (6.1575)
Changement de prix par mois: -23.53% (8.052)
Changement de prix sur 3 mois: -32.7% (9.15)
Changement de prix sur six mois: -34.7% (9.43)
Changement de prix par an: -38.43% (10)
Evolution du prix sur 3 ans: -63.61% (16.92)
Evolution du prix sur 5 ans: -23.32% (8.03)
Evolution des prix sur 10 ans: 0% (6.1575)
Evolution des prix depuis le début de l'année: -8.78% (6.75)

Sous-estimation

Nom Signification Grade
P/S 9 1
P/BV 0.0122 10
P/E 325.54 1
EV/EBITDA -550.44 0
Total: 4.25

Efficacité

Nom Signification Grade
ROA, % -0.0325 0
ROE, % -0.0764 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0.5 5
Total: 1.31

Devoir

Nom Signification Grade
Debt/EBITDA -1497.58 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -98.87 0
Rentabilité Ebitda, % -101.96 0
Rentabilité EPS, % -104.07 0
Total: 0



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Christopher Cargill Representative Executive Officer, President, CEO & Director 1.25M 1984 (41 année)
Mr. Hironoshin Nomura Executive Officer, Executive VP & CFO N/A 1983 (42 année)
Mr. Kieran Johnson F.C.A. Executive Officer, Executive VP & Chief Accounting Officer N/A 1969 (56 années)
Mr. Toshihiro Maeda Executive VP & COO N/A 1979 (46 années)
Mr. Kazuhiko Yoshizumi Executive Officer, Executive VP & Chief Compliance Officer N/A 1954 (71 année)
Shinichiro Nishishita VP of Investor Relations & Head of Regulatory Disclosures N/A
Stacey Southall Associate Director & Head of Biophysics N/A
Ms. Candelle Chong Executive Officer, Executive VP, CEO Office & Chief of Staff N/A 1989 (36 années)
Dr. Satoshi Tanaka Exe. Off., Executive VP and President of Idorsia Pharmaceuticals Japan & Nxera Pharma Japan N/A 1957 (68 années)
Dr. Shinichi Tamura Founder & Chairman of the Board 1949 (76 années)

Adresse: Japan, Tokyo -, PMO Hanzomon - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://soseiheptares.com